Instituto Rosenbusch S.A. (BCBA:ROSE)
Argentina · Delayed Price · Currency is ARS 154.50
+0.50 (0.32%)
At close: Sep 23, 2026
Instituto Rosenbusch Financials Overview
Financials in millions ARS. Fiscal year is January - December.
Millions ARS. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 7,296 | 6,404 | 10,886 | 9,860 | 4,276 | 1,523 |
Revenue Growth | -8.58% | -41.17% | 10.40% | 130.61% | 180.84% | 80.56% |
Gross Profit Gross Profit Growth | 14.9 | -286.03 | 4,980 | 2,825 | 1,974 | 429.2 |
Operating Income Operating Income Growth | -3,556 | -3,369 | 2,461 | 34.37 | 875.27 | 41.98 |
Net Income Net Income Growth | -209.41 | -4,598 | -1,864 | 1,226 | -25.22 | -38.12 |
Earnings Per Share EPS Growth | - | -107.95 | -43.78 | 28.78 | -0.59 | -0.90 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Biological Products Biological Products Growth | 2,308 | 5,973 | 5,961 | 2,030 | 821.71 |
Pharmaceutical products Pharmaceutical products Growth | 3,134 | 4,613 | 3,725 | 2,010 | 638.44 |
Other Other Growth | 165.11 | 299.73 | 174.06 | 235.76 | 62.37 |
Total Total Growth | 5,606 | 10,886 | 9,860 | 4,276 | 1,523 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 986.43 | 712.26 | 1,154 | 850.98 | 331.95 | 110.95 |
Total Debt Total Debt Growth | 3,068 | 1,450 | 2,289 | 2,251 | 1,074 | 372.01 |
Net Cash (Debt) Net Cash Growth | -2,081 | -737.74 | -1,135 | -1,400 | -742.22 | -261.06 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | - | -17.32 | -26.66 | -32.88 | -17.43 | -6.13 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 696.77 | 409.89 | 720.31 | 331.37 | 153.37 | 58.37 |
Capital Expenditures CapEx Growth | -9.67 | -12.13 | -13.65 | -115.45 | -82.63 | -4.18 |
Free Cash Flow Free Cash Flow Growth | 687.1 | 397.75 | 706.67 | 215.92 | 70.74 | 54.2 |
Free Cash Flow Growth | - | -43.71% | 227.27% | 205.25% | 30.52% | -13.68% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 0.20% | -4.47% | 45.75% | 28.65% | 46.16% | 28.19% |
Operating Margin | -48.74% | -52.61% | 22.61% | 0.35% | 20.47% | 2.76% |
Pretax Margin | -42.02% | -69.70% | -17.15% | 13.91% | 0.76% | -2.50% |
Profit Margin | -2.87% | -71.80% | -17.13% | 12.43% | -0.59% | -2.50% |
FCF Margin | 9.42% | 6.21% | 6.49% | 2.19% | 1.65% | 3.56% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 2.22 | - | - |
P/FCF Ratio | 9.58 | 25.75 | 7.35 | 12.62 | 7.77 | 8.64 |
PS Ratio | 0.90 | 1.60 | 0.48 | 0.28 | 0.13 | 0.31 |